Attorney Docket No. 5079P2 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yamin WANG, et al

Serial No.: to be assigned Group Number:

Filed: herewith Examiner:

For: 1,6-Naphthyridine Derivatives and their Use to Treat Diabetes and Related Disorders

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: MS Patent Applications, Commissioner for Patents, PO. Box 1450, Alexandria, VA 22313-1450.

Date: 10/10/2003 Monica McGovern

Monica McGovern

MS PATENT APPLICATIONS
ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir/Madam:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449. These references were cited in the applicant's Information Disclosure Statement for the corresponding US Patent Application (10/253,215).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed ***before*** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino

Reg. No. 48972

Telephone: (203) 812-6450

Date: 10/10/2003

Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/253,215	Group Art Unit 1614	Filing Date 09/23/02	Atty. Docket No. 5079 P2
INFORMATION DISCLOSURE CITATION		Applicant(s) Wang, et al.			

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	U1	6	3	0	6	8	5	6	10/23/01	S. Sawa	514	252.02	05/18/00
	U2	5	8	1	7	6	6	9	10/06/98	Tomita, et al.	514	300	12/13/96
	U3	5	2	1	7	9	7	6	06/08/93	Ratcliffe, et al.	514	300	05/29/92

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB-CLASS	TRANSLATION	
													YES	NO
	F1	0	2	2	7	0	8	8	01/07/87	EP				
	F2	0	0	0	8	0	2	6	17/02/00	WO				
	F3	9	8	0	5	6	6	1	12/02/98	WO				
	F4	0	0	7	1	5	2	4	30/11/00	WO				
	F5	0	0	1	6	7	7	4	30/03/00	WO				
	F6	2	2	5	6	1	9	6	02/12/92	GB				
	F7	0	8	5	6	3	1	0	05/08/98	EP				
	F8	0	5	1	6	3	9	2	02/12/92	EP				
	F9	0	3	6	6	6	4	3	02/05/90	EP				

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
	R1	Patent Abstract of Japan, Pub. No.: 03058992, Pub. Date: 14/03/91, App. Date: 28/07/89, App. No.: 01/196,205, "New Isothiazolo-Naphthylidine, Isothiazoloquinoline Derivative and Salt Thereof", Fukuoka Yoshikazu
	R2	Patent Abstract of Japan, Pub. No.: 03223289, Pub. Date: 02/10/91, App. Date: 21/11/90, App. No.: 02319358, "Thienoquinoline Derivative, Thienonaphthyridine Derivative And Salt Thereof", Nakada Katsuhisa
	R3	Hermecz, I., Horvath, A., "Nitrogen Bridgehead Compounds. Part 83 [1]. Synthesis and Ring Transformation of 6-Methyl-4-oxo-4H-pyrido[1,2-a]Pyrimidine-3-Acrylates", J. Heterocyclic Chem., 29: 559-564 (1992)
	R4	Chu, D., Claiborne, A., "Practical Synthesis of Iminochlorothioformates: Application of Iminochlorothioformates in the Synthesis of Novel 2,3,4,9-Tetrahydroisothiazolo[5,4-b][1,8]Naphthyridine-3,4-Diones and 2,3,4,9-Tetrahydroisothiazolo[5,4-b]Quinoline-3,4-Dione Derivatives", J. Heterocyclic Chem., 27: 1191-1195 (1990)
	R5	Ming, Y., Horlemann, N., Wamhoff, H., "Heterocondensed Pyridines by Cycloaddition-Extrusion Sequence of Bi- and Tricyclic 1,3-Oxazinones With N,N-Diethyl-1-Propynylamine", Chemische Berichte, 120: 1427-1431 (1987)
	R6	Friary, R., Seidl, V., Schwerdt, J., Cohen, M., Hou, D., Nafissi, M., "Intramolecular Transaminations of Enaminones: A Synthesis of Fused, Polycyclic, N-Aryl Pyridones", Tetrahedron, 49: 7169-7178 (1993)
	R7	Osborne, A., Goolamali, Z., "^{1}H and ^{13}C NMR Spectra; Studies of Some 4H-3, 1-Benzoxazin-4-Ones and Their 2-Acylaminobenzoic Acid Precursors", Spectrochimica Acta Part A, 56: 1079-1100 (2000)
	R8	Patent Abstracts of Japan, Patent No.:JP 09221424, Date: 19970826, "Antitumor Agent", Kyoji, T., Katsumi, C., Shigeki, K., Katsuhisa, N., Kouichirou, S., Yasutomo, C., Masanori, T., Tomio, O.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	